IBO
Impact BioMedical·AMEX
--
--(--)
--
--(--)
IBO fundamentals
During Q4 2025, Impact BioMedical (IBO) reported revenue of 7.00K, a YoY change of 0.00%. Net income was 5.24M, a YoY change of 119.29%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 50.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 7.00K -- | 18.00K -- | 7.00K -- | -- -- |
Sales and Services Revenue | 50.00K -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 7.00K -- | 18.00K -- | 7.00K -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 11.00K -- | 1.00K -- | 422.00K -- | -- -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 11.00K -- | 1.00K -- | 422.00K -- | -- -- |
Gross Profit | 50.00K -- | -- -- | -50.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -4.00K -- | 17.00K -- | -415.00K -- | -- -- |
Operating Expenses | 800.00K -- | 889.00K -- | 1.03M -- | 803.00K -- | 1.01M +26.00% | 1.08M +21.26% | 1.14M +10.37% | 771.00K -3.99% | 626.00K -37.90% | 1.13M +4.55% | 26.23M +2202.99% | 1.01M +31.00% | 1.15M +83.55% | 965.00K -14.37% | 755.00K -97.12% | 3.88M -- |
Selling, General and Administrative Expenses | 336.00K -- | 376.00K -- | 1.07M -- | 337.00K -- | 331.00K -1.49% | 715.00K +90.16% | 408.00K -61.76% | 581.00K +72.40% | 442.00K +33.53% | 874.00K +22.24% | 1.17M +185.54% | 773.00K +33.05% | 535.00K +21.04% | 551.00K -36.96% | 1.41M +21.12% | 3.27M -- |
Selling and Marketing Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | 17.00K -- | 21.00K -- | 8.00K -- | 18.00K -- | 461.00K +2611.76% | 146.00K +595.24% | 19.00K +137.50% | 1.00K -94.44% | 2.00K -99.57% | 2.00K -98.63% | 24.00K -- |
General and Administrative Expenses | -- -- | -- -- | 68.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Research and Development Expenses | 206.00K -- | 330.00K -- | 522.00K -- | 179.00K -- | 266.00K +29.13% | 357.00K +8.18% | 630.00K +20.69% | 183.00K +2.23% | 121.00K -54.51% | 82.00K -77.03% | -108.00K -117.14% | 103.00K -43.72% | 75.00K -38.02% | 52.00K -36.59% | 110.00K +201.85% | 340.00K -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 25.36M -- | -- -- | -- -- | -- -- | 0 -100.00% | -- -- |
Loss on Disposal of Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 12.00K -- | -- -- |
Other Operating Expenses | 258.00K -- | 183.00K -- | -557.00K -- | 287.00K -- | 411.00K +59.30% | 6.00K -96.72% | 101.00K +118.13% | 7.00K -97.56% | 63.00K -84.67% | 171.00K +2750.00% | -182.00K -280.20% | 134.00K +1814.29% | 539.00K +755.56% | 362.00K +111.70% | -778.00K -327.47% | 257.00K -- |
Operating Income | -750.00K -- | -889.00K -- | -1.03M -- | -803.00K -- | -1.01M -34.40% | -1.08M -21.26% | -1.14M -10.37% | -771.00K +3.99% | -626.00K +37.90% | -1.13M -4.55% | -26.23M -2202.99% | -1.01M -31.00% | -1.15M -84.19% | -948.00K +15.88% | -1.17M +95.54% | -4.28M -- |
Non-Operating Income (Loss) | -49.00K -- | -89.00K -- | -4.21M -- | -46.00K -- | -113.00K -130.61% | -99.00K -11.24% | -122.00K +97.10% | -227.00K -393.48% | -258.00K -128.32% | 5.37M +5522.22% | -869.00K -612.30% | -268.00K -18.06% | -13.20M -5015.89% | -527.00K -109.82% | 3.83M +540.16% | -10.17M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | 0 -- | 5.67M -- | -602.00K -- | -- -- | -12.94M -- | -268.00K -104.73% | 3.82M +734.88% | -- -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -4.03M -- | 52.00K -- | -- -- | 0 -- | 0 +100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | 49.00K -- | 89.00K -- | 179.00K -- | 98.00K -- | 113.00K +130.61% | 99.00K +11.24% | 122.00K -31.84% | 227.00K +131.63% | 258.00K +128.32% | 302.00K +205.05% | 267.00K +118.85% | 268.00K +18.06% | 257.00K -0.39% | 259.00K -14.24% | -3.00K -101.12% | 781.00K -- |
Interest Expense | 139.00K -- | 92.00K -- | 99.00K -- | 101.00K -- | 116.00K -16.55% | 102.00K +10.87% | 125.00K +26.26% | 230.00K +127.72% | 261.00K +125.00% | 305.00K +199.02% | 270.00K +116.00% | 271.00K +17.83% | 260.00K -0.38% | 262.00K -14.10% | 0 -100.00% | 793.00K -- |
Interest Income | 90.00K -- | 3.00K -- | -80.00K -- | 3.00K -- | 3.00K -96.67% | 3.00K -- | 3.00K +103.75% | 3.00K -- | 3.00K -- | 3.00K -- | 3.00K -- | 3.00K -- | 3.00K -- | 3.00K -- | 3.00K -- | 12.00K -- |
Pretax Income From Continuing Operations | -799.00K -- | -978.00K -- | -5.25M -- | -849.00K -- | -1.12M -40.30% | -1.18M -20.35% | -1.26M +75.96% | -998.00K -17.55% | -884.00K +21.14% | 4.24M +460.32% | -27.10M -2049.09% | -1.28M -28.06% | -14.35M -1523.53% | -1.48M -134.78% | 2.65M +109.80% | -14.45M -- |
Income Tax Expense | -- -- | 1.26M -- | -1.88M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 33.00K -- | -- -- | -- -- | 0 -- | -2.58M -7918.18% | -- -- |
Current Income Tax | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- |
Deferred Income Tax | -- -- | -- -- | -1.78M -- | -- -- | -- -- | -- -- | -1.01M +43.16% | -- -- | -- -- | -- -- | 33.00K +103.25% | -- -- | -- -- | -- -- | -2.26M -6954.55% | -- -- |
Income Tax Adjustments | -- -- | -- -- | 1.16M -- | -- -- | -- -- | -- -- | 1.01M -12.81% | -- -- | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -318.00K -- | -- -- |
Net Income | -799.00K -- | -2.24M -- | -3.37M -- | -849.00K -- | -1.12M -40.30% | -1.18M +47.36% | -1.26M +62.54% | -998.00K -17.55% | -884.00K +21.14% | 4.24M +460.32% | -27.13M -2051.70% | -1.28M -28.06% | -14.35M -1523.53% | -1.48M -134.78% | 5.24M +119.29% | -11.87M -- |
Net Income Attributable to Minority Interests | -67.00K -- | -67.00K -- | -4.00K -- | -192.00K -- | -19.00K +71.64% | -15.00K +77.61% | -26.00K -550.00% | -36.00K +81.25% | 5.00K +126.32% | -6.00K +60.00% | -25.00K +3.85% | -11.00K +69.44% | -6.00K -220.00% | -5.00K +16.67% | -10.00K +60.00% | -32.00K -- |
Net Income Attributable to Owners of the Company | -732.00K -- | -2.17M -- | -3.36M -- | -657.00K -- | -1.10M -50.55% | -1.16M +46.43% | -1.24M +63.27% | -962.00K -46.42% | -889.00K +19.33% | 4.25M +465.49% | -27.11M -2094.98% | -1.27M -31.70% | -14.35M -1513.72% | -1.47M -134.61% | 5.25M +119.35% | -11.84M -- |
Net Income Attributable to Common Stockholders | -732.00K -- | -2.17M -- | -3.36M -- | -657.00K -- | -1.10M -50.55% | -1.16M +46.43% | -1.24M +63.27% | -962.00K -46.42% | -889.00K +19.33% | 4.25M +465.49% | -27.11M -2094.98% | -1.27M -31.70% | -14.35M -1513.72% | -1.47M -134.61% | 5.25M +119.35% | -11.84M -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 4.24M -- | -2.36M -- | -- -- | -- -- | -1.48M -134.78% | 17.11M +823.87% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -884.00K -- | 4.24M -- | -2.36M -- | -- -- | -14.35M -1523.53% | -1.48M -134.78% | 17.11M +823.87% | -- -- |
Basic EPS | -0.01 -- | -0.03 -- | -- -- | -0.01 -- | -0.02 -100.00% | -0.02 +33.33% | -- -- | -0.1 -900.00% | -0.09 -350.00% | 0.37 +1950.00% | -2.36 -- | -0.11 -10.00% | -1.18 -1211.11% | -0.12 -132.43% | 0.05 +102.12% | -1.36 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -0.02 -- | -- -- | -0.1 -- | -0.09 -- | 0.37 +1950.00% | -- -- | -0.11 -10.00% | -1.18 -1211.11% | -0.12 -132.43% | -- -- | -- -- |
Diluted EPS | -0.01 -- | -0.03 -- | -- -- | -0.01 -- | -0.02 -100.00% | -0.02 +33.33% | -- -- | -0.1 -900.00% | -0.09 -350.00% | 0.06 +400.00% | -- -- | -0.11 -10.00% | -1.18 -1211.11% | -0.12 -300.00% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -0.02 -- | -- -- | -0.1 -- | -0.09 -- | 0.06 +400.00% | -- -- | -0.11 -10.00% | -1.18 -1211.11% | -0.12 -300.00% | -- -- | -- -- |
You can ask Aime
What is the market's earnings forecast for Impact BioMedical next quarter?What were the key takeaways from Impact BioMedical's earnings call?What guidance did Impact BioMedical's management provide for the next earnings period?What is the revenue and EPS growth rate for Impact BioMedical year over year?What does Impact BioMedical do and what are its main business segments?What factors drove the changes in Impact BioMedical's revenue and profit?Did Impact BioMedical beat or miss consensus estimates last quarter?What is Impact BioMedical's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
